Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (Nasdaq: BBIO) announced that on December 18, 2025 its compensation committee approved inducement restricted stock unit grants to 9 new employees totaling 29,472 shares of common stock.
Vesting: one‑quarter of each award vests on November 16, 2026, then one‑twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended in February and December 2023, and cited Nasdaq Listing Rule 5635(c)(4) as the inducement basis.
BridgeBio (Nasdaq: BBIO) said members of management will participate in two December investor fireside chats: Piper Sandler Healthcare Conference in New York on Tuesday, December 2 at 10:30 AM ET, and EvercoreISI HealthCONx Conference in Miami on Wednesday, December 3 at 3:00 PM ET.
Live webcasts will be available on the company’s Investors > Events and Presentations page, with replays accessible on the BridgeBio website for 90 days after each event.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved on November 17, 2025 for 12 new employees totaling 34,199 restricted stock units. Awards vest: one-quarter on November 16, 2026, then one-twelfth of the remainder quarterly thereafter, subject to continued employment.
All awards were granted under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan and were designated as inducement grants under Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted in November 2019 and amended in February and December 2023.
BridgeBio (Nasdaq: BBIO) on Nov 8, 2025 reported JAMA Cardiology and AHA data showing acoramidis (Attruby) significantly reduced mortality in variant ATTR-CM populations.
Key results: 59% lower all-cause mortality (ACM) in variant patients through Month 42 (p=0.032); in the p.V142I (V142I, V122I) subgroup a 69% reduction in ACM/first cardiovascular hospitalization through Month 30 (p=0.016) and 69% ACM reduction through Month 42 (p=0.045). Functional gains included +87 m 6-minute walk (p=0.0048) and +20 points KCCQ (p=0.0019) through Month 30. The V142I variant affects ~3–4% of U.S. Black individuals. Attruby is approved by FDA and major regulators in EU, UK, and Japan.
BridgeBio (Nasdaq: BBIO) said members of its management team will present at two investor conferences in November 2025: a fireside chat at the UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10 at 1:15 pm ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18 at 11:00 am ET.
The company said live webcasts will be available on its Investors > Events and Presentations page and replay recordings will remain on the BridgeBio website for 90 days after each event.
BridgeBio (Nasdaq: BBIO) will present ten moderated digital posters at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The posters report clinical findings from the ATTRibute-CM study, including data on acoramidis showing reductions in all-cause mortality and cardiovascular hospitalizations, benefits across pre-specified subgroups, effects in the p.V142I (V122I) variant population, and NT-proBNP and quality-of-life improvements.
Presentations are scheduled Nov 8–10 with lead presenters from major centers (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington, and others). A separate poster covers vutrisiran real-world healthcare resource use and mortality from a retrospective database analysis.
BridgeBio (Nasdaq: BBIO) reported Q3 2025 revenue of $120.7M, driven by $108.1M in U.S. Attruby net product sales. As of Oct 25, 2025, 5,259 prescriptions from 1,355 prescribers were written since FDA approval in Nov 2024. The company ended the quarter with $645.9M in cash, cash equivalents and marketable securities.
Clinical highlights include positive topline FORTIFY results for BBP-418 (glycosylated αDG increased 1.8x at 3 months; serum CK reduced 82%; ambulation and FVC improvements) and positive CALIBRATE results for encaleret (76% of participants achieved serum and urine calcium targets at Week 24 vs 4% on conventional therapy). BridgeBio plans NDAs for BBP-418 and encaleret in 1H 2026.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 results from CALIBRATE for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The trial met its primary and key secondary endpoints with 76% of encaleret-treated participants reaching target serum and urine calcium at Week 24 versus 4% on conventional therapy (p<0.0001), and 91% achieving intact PTH above the lower reference limit versus 7% on conventional therapy (p<0.0001).
Additional readouts: mean corrected calcium increase of 0.82 mg/dL, mean 24-hour urine calcium reduction of 200 mg/day, 98% in target serum calcium at Week 20, and no discontinuations due to study drug. An NDA submission is planned in H1 2026; pediatric and chronic hypoparathyroidism registrational studies are planned in 2026.
BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.
Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 FORTIFY results for oral small molecule BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on Oct 27, 2025. Key clinical and biomarker readouts at the planned 12-month interim analysis met endpoints with a favorable safety profile.
Highlights include a 1.8x increase in glycosylated αDG (~17% of control, p<0.0001) sustained to 12 months, an 82% reduction in serum CK (p<0.0001), ambulatory improvement of +0.14 m/s from baseline and +0.27 m/s vs placebo (p<0.0001), and pulmonary benefit of ~+3% predicted FVC from baseline and ~+5% vs placebo (p=0.0071). The company intends to file an NDA with the FDA in H1 2026.